Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Key determinants of self-management in patients with non-dialysis-dependent chronic kidney disease: a systematic review.

Public health reviews·2026
Same author

Once-Weekly Subcutaneous Insulin Efsitora for the Management of Diabetes Mellitus: A Systematic Review and Meta-Analysis Study.

Medeniyet medical journal·2026
Same author

Extraoral Detection of Biomarkers and Pathogens in Saliva: Comprehensive, Panoramic Review.

Biosensors·2026
Same author

Epidemiology, outcomes of treatment, and survival of cervical cancer in Kazakhstan: a nationwide population-based study.

Frontiers in oncology·2026
Same author

Comparative efficacy and safety of transcatheter edge-to-edge repair versus tricuspid valve replacement versus optimal medical therapy in moderate-to-severe tricuspid regurgitation: a network meta-analysis of randomized controlled trials.

Journal of cardiothoracic surgery·2026
Same author

Emerging Urinary Biomarkers and Innovative Technologies for the Early Detection and Personalized Management of Chronic Kidney Disease.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jul 4, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

Gabapentinoids for Neuropathic Pain Management: A Systematic Umbrella Review.

Bermet Nurmukhamed1, Aliya Baizhanova1, Shyrailym Inayat1

  • 1Department of Surgery, School of Medicine, Nazarbayev University, Astana, Kazakhstan.

Current Neuropharmacology
|July 3, 2026
PubMed
Summary

This umbrella review found gabapentinoids effective for certain neuropathic pain conditions, but most studies were low quality. Side effects like dizziness and somnolence are common with gabapentinoids.

Keywords:
Gabapentinoidschronic paingabapentinneuralgianeuropathic painpain managementpain modulationperipheral nervous system diseasespregabalinsystematic review

More Related Videos

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
08:16

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies

Published on: October 6, 2022

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
09:03

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management

Published on: March 28, 2025

Related Experiment Videos

Last Updated: Jul 4, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
08:16

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies

Published on: October 6, 2022

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
09:03

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management

Published on: March 28, 2025

Area of Science:

  • Neurology
  • Pharmacology
  • Pain Management

Background:

  • Neuropathic pain affects millions globally, necessitating effective management strategies.
  • Gabapentinoids are commonly prescribed for neuropathic pain, but their efficacy and safety require thorough evaluation.
  • Existing evidence is fragmented, highlighting the need for a comprehensive synthesis.

Purpose of the Study:

  • To conduct an umbrella review evaluating the effectiveness of gabapentinoids for neuropathic pain.
  • To assess dosing strategies and the risk profile associated with gabapentinoid use.
  • To synthesize evidence from systematic reviews and meta-analyses on gabapentinoids in various neuropathic pain conditions.

Main Methods:

  • Systematic search for systematic reviews and meta-analyses adhering to PRISMA standards.
  • Quality assessment of included studies using the Assessment of Multiple Systematic Reviews 2 (AMSTAR 2) tool.
  • Inclusion of studies covering neuropathic pain in spinal cord injury, post-herpetic neuralgia, cancer, diabetes, refractory pain, and sciatica.

Main Results:

  • 22 systematic reviews and meta-analyses were included; 19 were critically low quality.
  • Mirogabalin showed superior efficacy over pregabalin for lower limb neuropathic pain.
  • Pregabalin demonstrated a greater short-term pain reduction than gabapentin; both linked to dizziness and somnolence.

Conclusions:

  • Gabapentinoids demonstrated efficacy in diabetic peripheral neuropathic pain, cancer-related neuropathic pain, and spinal cord injury.
  • Efficacy was also noted in refractory neuropathic pain conditions, though results for post-herpetic neuralgia were controversial.
  • Critically low study quality limits confidence; gabapentinoids are associated with side effects like drowsiness, edema, and weight gain.